Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05614986 · ClinicalTrials.gov registry record
Prospective Evaluation of Neurocognition in Patients Undergoing Transcatheter Aortic Valve Replacement
A clinical trial, sponsored by Baylor Research Institute.
- Completed
- Registry status
- 81
- Enrollment target
NCT05614986: Completed study, sponsored by Baylor Research Institute.
NCT05614986 is a clinical trial that has completed, run by Baylor Research Institute. The registered enrollment target is 81 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05614986 has completed, sponsored by Baylor Research Institute.
- COMPLETED
- Registry status
- 81 participants
- Enrollment target
Study Summary
This trail is for patients with mild cognitive impairment (MCI) who are receiving a transcatheter aortic valve replacement (TAVR). We will assess changes in neurocognition following TAVR with the 5 minute Montreal Cognitive Assessment (mini MoCA) when comparing pre procedure with post procedure assessments.
Primary Outcome
Changes in neurocognition compared to baseline at 30 days
Interventions
- OTHER 5 minute Montreal Cognitive Assessment (mini MoCA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2022-01-17 |
| Est. Completion | 2024-02-27 |
What the finished NCT05614986 record still lists
NCT05614986 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 81 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which 5 minute Montreal Cognitive Assessment (mini MoCA) is the first listed.
NCT05614986 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05614986 about?
NCT05614986 is a clinical study titled "Prospective Evaluation of Neurocognition in Patients Undergoing Transcatheter Aortic Valve Replacement". This trail is for patients with mild cognitive impairment (MCI) who are receiving a transcatheter aortic valve replacement (TAVR). We will assess changes in neurocognition following TAVR with the 5 minute Montreal Cognitive Assessment (mini MoCA) when comparing pre procedure with post procedure asse...
What is the current status of trial NCT05614986?
This trial is currently completed. The enrollment target is 81 participants. The study started on 2022-01-17. Estimated completion is 2024-02-27.
What interventions are being tested in trial NCT05614986?
The interventions under investigation include: 5 minute Montreal Cognitive Assessment (mini MoCA) (OTHER).
Who is sponsoring clinical trial NCT05614986?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI